Gernot Zissel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1447560/publications.pdf

Version: 2024-02-01

97 papers	5,830 citations	71102 41 h-index	76900 74 g-index
102 all docs	102 docs citations	102 times ranked	6989 citing authors

#	Article	IF	Citations
1	A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust. Chest, 2021, 159, 1084-1093.	0.8	14
2	Surveillance Bronchoscopy for the Care of Lung Transplant Recipients: A Retrospective Single Center Analysis. Transplantation Proceedings, 2021, 53, 265-272.	0.6	4
3	Analysis of single nucleotide polymorphisms in chronic beryllium disease. Respiratory Research, 2021, 22, 107.	3.6	1
4	Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer. Data in Brief, 2021, 35, 106859.	1.0	3
5	Development of a new methodology to determine size differences of nanoparticles with nanoparticle tracking analysis. Applied Nanoscience (Switzerland), 2021, 11, 2129-2141.	3.1	4
6	Response. Chest, 2021, 159, 2509-2510.	0.8	0
7	Vasoactive Intestinal Peptide in Checkpoint Inhibitorâ€“Induced Pneumonitis. New England Journal of Medicine, 2020, 382, 2573-2574.	27.0	17
8	Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30. Anticancer Research, 2020, 40, 3097-3108.	1.1	3
9	Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) â€“ protocol for a multi-center, single-arm phase IIa trial. Contemporary Clinical Trials Communications, 2020, 19, 100575.	1.1	10
10	Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease. Frontiers in Immunology, 2020, 11, 616832.	4.8	12
11	Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients. Transplantation, 2019, 103, 815-822.	1.0	40
12	Human alveolar epithelial cells type II are capable of TGFÎ²-dependent epithelial-mesenchymal-transition and collagen-synthesis. Respiratory Research, 2018, 19, 138.	3.6	52
13	Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. Pathology and Oncology Research, 2017, 23, 723-730.	1.9	7
14	Sarcoidosis: Drugs under Investigation. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 532-537.	2.1	5
15	Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota. European Respiratory Journal, 2017, 50, 1600746.	6.7	46
16	P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. Frontiers in Immunology, 2017, 8, 1028.	4.8	27
17	Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?. PLoS ONE, 2017, 12, e0185350.	2.5	5
18	The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. Oncotarget, 2017, 8, 35962-35972.	1.8	28

#	Article	IF	Citations
19	Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations. Frontiers in Immunology, 2016, 7, 274.	4.8	18
20	Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 749-757.	2.9	29
21	Specific antigen(s) in sarcoidosis: a link to autoimmunity?. European Respiratory Journal, 2016, 47, 707-709.	6.7	13
22	Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease. Anticancer Research, 2016, 36, 4667-4672.	1.1	8
23	Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis. Respiratory Research, 2015, 16, 105.	3.6	28
24	Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0116775.	2.5	170
25	Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer. Lung Cancer, 2015, 90, 516-521.	2.0	35
26	Cellular Players in the Immunopathogenesis of Sarcoidosis. Clinics in Chest Medicine, 2015, 36, 549-560.	2.1	39
27	Are bronchoalveolar lavages a good source for microbial profiling? Differences between throat and bronchoalveolar lavage microbiomes. Journal of Medical Microbiology, 2015, 64, 948-951.	1.8	12
28	The chemokine CCL18 characterisesPseudomonasinfections in cystic fibrosis lung disease. European Respiratory Journal, 2014, 44, 1608-1615.	6.7	16
29	Cellular Activation in the Immune Response of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 307-315.	2.1	25
30	mRNA and miRNA analyses in cytologically positive endobronchial ultrasoundâ€guided transbronchial needle aspiration: Implications for molecular staging in lung cancer patients. Cancer Cytopathology, 2014, 122, 292-298.	2.4	11
31	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care and Research, 2013, 65, 281-287.	3.4	15
32	Genome-wide association analysis reveals 12q13.3â€“q14.1 as new risk locus for sarcoidosis. European Respiratory Journal, 2013, 41, 888-900.	6.7	43
33	CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Elevates the Invasive Potential. PLoS ONE, 2013, 8, e53068.	2.5	45
34	Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation. PLoS ONE, 2013, 8, e81382.	2.5	102
35	Tumor-Cell Co-Culture Induced Alternative Activation of Macrophages Is Modulated by InterferonsIn Vitro. Journal of Interferon and Cytokine Research, 2012, 32, 169-177.	1.2	30
36	A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 877-885.	5.6	51

#	Article	IF	Citations
37	CCL18 â€" Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis. Journal of Rheumatology, 2012, 39, 1407-1412.	2.0	14
38	Pathogenesis of sarcoidosis. Presse Medicale, 2012, 41, e275-e287.	1.9	44
39	Roflumilast-N-oxide Induces Surfactant Protein Expression in Human Alveolar Epithelial Cells Type II. PLoS ONE, 2012, 7, e38369.	2.5	5
40	Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas. PLoS ONE, 2012, 7, e41746.	2.5	29
41	Purinergic Receptor Type 6 Contributes to Airway Inflammation and Remodeling in Experimental Allergic Airway Inflammation. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 215-223.	5.6	85
42	P2X₇ Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 423-429.	2.9	130
43	Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung. British Journal of Cancer, 2011, 105, 673-681.	6.4	6
44	Alternatively activated alveolar macrophages in pulmonary fibrosisâ€"mediator production and intracellular signal transduction. Clinical Immunology, 2010, 137, 89-101.	3.2	268
45	Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation. Clinical and Experimental Allergy, 2010, 40, 1552-1560.	2.9	11
46	Extracellular Adenosine Triphosphate and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 928-934.	5.6	174
47	Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema. Journal of Immunology, 2010, 185, 688-697.	0.8	119
48	Immunologic Response of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 390-403.	2.1	82
49	Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 540-548.	5.6	146
50	Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 717-723.	5.6	290
51	The Hidden Macrophage. Respiration, 2009, 77, 129-131.	2.6	0
52	CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers. Inflammation, 2009, 32, 163-168.	3.8	16
53	Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. American Journal of Pathology, 2009, 174, 1683-1691.	3.8	59
54	Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma. Respirology, 2008, 13, 1022-1027.	2.3	12

#	Article	IF	Citations
55	Interleukinâ€13 acts as an apoptotic effector on lung epithelial cells and induces proâ€fibrotic gene expression in lung fibroblasts. Clinical and Experimental Allergy, 2008, 38, 619-628.	2.9	43
56	Genetics of Sarcoidosis. Clinics in Chest Medicine, 2008, 29, 391-414.	2.1	80
57	Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion. Journal of Immunology, 2008, 181, 2181-2188.	0.8	57
58	Phenotyping Sarcoidosis from a Pulmonary Perspective. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 330-336.	5.6	137
59	Serotoninergic Receptors on Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 85-93.	2.9	65
60	Sarcoidosis-Immunopathogenetic Concepts. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 003-014.	2.1	86
61	Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. European Respiratory Journal, 2007, 29, 976-985.	6.7	315
62	IL-10â€“producing monocytes differentiate to alternatively activated macrophages and areÂincreased in atopic patients. Journal of Allergy and Clinical Immunology, 2007, 119, 464-471.	2.9	55
63	CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 1685-1693.	6.7	202
64	Pulmonary TH2 response in Pseudomonas aeruginosaâ€“infected patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2006, 117, 204-211.	2.9	172
65	A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 781-792.	5.6	403
66	Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. International Journal of Molecular Medicine, 2006, 18, 925.	4.0	7
67	Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis. FEMS Immunology and Medical Microbiology, 2006, 46, 30-38.	2.7	19
68	Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1370-1376.	5.6	83
69	Genotype-corrected reference values for serum angiotensin-converting enzyme. European Respiratory Journal, 2006, 28, 1085-1091.	6.7	66
70	Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. European Respiratory Journal, 2006, 27, 1190-1195.	6.7	116
71	Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. International Journal of Molecular Medicine, 2006, 18, 925-31.	4.0	20
72	The P2Y14 Receptor of Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 601-609.	2.9	90

#	Article	IF	Citations
73	CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respiratory Research, 2005, 6, 75.	3.6	43
74	A role for MCP-1/CCR2 in interstitial lung disease in children. Respiratory Research, 2005, 6, 93.	3.6	44
75	Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. Journal of Allergy and Clinical Immunology, 2005, 115, 728-736.	2.9	70
76	Acute lung affection in an endurance-trained man under amiodarone medication. GMS German Medical Science, 2005, 3, Doc03.	2.7	0
77	The Serotoninergic Receptors of Human Dendritic Cells: Identification and Coupling to Cytokine Release. Journal of Immunology, 2004, 172, 6011-6019.	0.8	190
78	HOPE-Fixation Enables Improved PCR-Based Detection and Differentiation of Mycobacterium tuberculosis Complex in Paraffin-Embedded Tissues. Pathology Research and Practice, 2003, 199, 619-623.	2.3	23
79	Alveolar macrophages are the main source for tumour necrosis factorâ€Î± in patients with sarcoidosis. European Respiratory Journal, 2003, 21, 421-428.	6.7	97
80	Systemic Immune Cell Activation in a Subgroup of Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2003, 70, 262-269.	2.6	34
81	Human alveolar epithelial cells induce nitric oxide synthaseâ€2 expression in alveolar macrophages. European Respiratory Journal, 2002, 19, 672-683.	6.7	38
82	Prostaglandin E2reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Letters, 2002, 518, 154-158.	2.8	58
83	Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 185-90.	0.2	64
84	Formation of Granulomas in the Lungs of Severe Combined Immunodeficient Mice after Infection with Bacillus Calmette-Guerin. American Journal of Pathology, 2001, 158, 1890-1891.	3.8	9
85	Accessory Function and Costimulatory Molecule Expression of Alveolar Macrophages in Patients with Pulmonary Tuberculosis. Immunobiology, 2000, 201, 450-460.	1.9	6
86	Analysis of the Kveim-Siltzbach Test Reagent for Bacterial DNA. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1981-1984.	5.6	33
87	Pharmacological modulation of the IFNÎ³-induced accessory function of alveolar macrophages and peripheral blood monocytes. Inflammation Research, 1999, 48, 662-668.	4.0	12
88	POLYMORPHISMS AT POSITION â^'308 IN THE PROMOTER REGION OF THE TNF-Î± AND IN THE FIRST INTRON OF THE TNF-Î² GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-Î± RELEASE IN SARCOIDOSIS. Cytokine, 1999, 11, 882-887.	3.2	55
89	Sarcoidosis: historical perspective and immunopathogenesis (part I). Respiratory Medicine, 1998, 92, 126-139.	2.9	24
90	Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 762-768.	5.6	120

#	Article	IF	Citations
91	Sarcoidosis: TNF- Î± Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1586-1592.	5.6	228
92	TCR V Î² Families in T Cell Clones from Sarcoid Lung Parenchyma, BAL, and Blood. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1593-1600.	5.6	22
93	Anti-<I>Borrelia burgdorferi</I> immunoglobulin seroprevalence in pulmonary sarcoidosis: a negative report. European Respiratory Journal, 1997, 10, 1356-1358.	6.7	22
94	Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis. Lung, 1997, 175, 105-116.	3.3	20
95	Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 713-719.	5.6	83
96	Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunology, Immunotherapy, 1996, 42, 122-126.	4.2	11
97	Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis. Lung, 1996, 174, 243-53.	3.3	17